BioRestorative Secures Australian Patent No. 2020265664 for ThermoStem Cell Therapy
IP Australia has allowed Patent Application No. 2020265664, granting broad protection for BioRestorative’s ThermoStem cell therapy targeting obesity and metabolic disorders. Shares fell nearly 10% after the announcement as the patent enhances the company’s global IP portfolio and competitive position versus GLP-1 drugs.
1. Patent Allowed by IP Australia
IP Australia has allowed Patent Application No. 2020265664, titled “Non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates, and methods of generating and using the same.” The allowance provides the broadest protection yet for BioRestorative’s allogeneic, off-the-shelf ThermoStem® technology.
2. Strategic Impact on ThermoStem Program
The Australian patent extends BioRestorative’s global IP coverage for its BADSC-based therapy, strengthening its competitive moat against GLP-1 drugs by safeguarding methods to produce and use brown adipose-derived stem cell aggregates for obesity and metabolic disorder treatments.
3. Market Reaction and Valuation Implications
Following the patent allowance announcement, BioRestorative’s shares declined almost 10%, indicating investor focus on near-term catalysts despite the long-term strategic value of enhanced IP protection. Analysts may revise valuation models to incorporate the expanded patent estate.
4. Executive Perspective
CEO Lance Alstodt emphasized that adding the Australian patent to the company’s growing portfolio underscores its commitment to advancing ThermoStem® as a next-generation, cell-based alternative to GLP-1 therapies with potential for longer-lasting efficacy and improved safety.